Cannabis Sativa

HortaPharm B.V.
IndustryHorticulture
FounderDavid Paul Watson
Headquarters,
ProductsCannabis seeds and clones

HortaPharm B.V. is a cannabis research business headquartered in the Netherlands.[1]

History[edit]

The business was founded by American David Watson also known as Sam Selezny or 'SkunkMan Sam' in the early 1990s, with seeds obtained from Sacred Seeds in California. David, Pate, Michael Taylor (aka Michael Rich), and Robert C. Clarke are early co-founders of the company.[2] From September 1994 until September 1997 HortaPharm had a permit from the Dutch Ministry of Health for scientific research of cannabis; this permit was rescinded due to compliance issues. In 1998, HortaPharm B.V. began work with GW Pharmaceuticals to develop cannabis strains for the manufacture of pharmaceuticals.[3]

Research[edit]

HortaPharm B.V. has used selective breeding and production for research of cannabis strains, with a focus on the isolation of tetrahydrocannabinol or cannabidiol.[4] GW Pharmaceuticals has exclusive rights to all genetics produced by HortaPharm B.V with the goal of producing one-off sterile female plants to control supply.[5] Co-founder David Pate gave a lecture at the National Academy of Sciences in Washington, D. C. on February 24, 1998, as part of the Institute of Medicine study to evaluate the therapeutic value of marijuana and its chemical components.[6]

Patents[edit]

In March of 2000, HortaPharm B.V. filed a patent for a vaporizer with enhanced isolation chambers for ascending-steam extraction, with the invention attributed to David Pate. [7] GW Pharmecuticals have filed multiple patents based on their work with HortaPham B.V. and the inventions of David Pate.[8]

References[edit]


Leave a Reply